High Risk Neuroblastoma (DBCOND0020366)

Identifiers

Synonyms

High-Risk Neuroblastoma / High risk Neuroblastoma

Associated Data

Indicated Drugs and Targets

Drug	Description	Targets
Dinutuximab	An immunotherapeutic agent used in combination with other immunomodulating agents to treat high-risk neuroblastoma in pediatric patients who achieve at least a partial response to prior first-line multiagent, multimodality therapy.	GD2 disialogangliosidetarget
Eflornithine	An ornithine decarboxylase inhibitor used to prevent relapse of high-risk neuroblastoma in pediatric and adult patients	Ornithine decarboxylasetarget

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT05373901	Evaluation of the Safety and Pharmacokinetics of Dinutuximab Beta As Maintenance Therapy in Chinese Participants With High-Risk Neuroblastoma	Dinutuximab Isotretinoin	treatment	1	completed
NCT05489887	Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma	Ceritinib Naxitamab	treatment	2	recruiting
NCT05650749	GPC2 CAR T Cells for Relapsed or Refractory Neuroblastoma	No drug interventions	treatment	1	recruiting
NCT06057948	A Study of a Vaccine in Combination With Beta-glucan in People With Neuroblastoma	Adagloxad simolenin QS-21	treatment	2	recruiting
NCT06480526	Feasibility of Screening for Early Late Effects of Contemporary Therapy in High-Risk Neuroblastoma Survivors	No drug interventions	Not Available	Not Available	recruiting
NCT06528496	N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma	Carboplatin Cyclophosphamide Doxorubicin Etoposide Ifosfamide Irinotecan Naxitamab Sargramostim Temozolomide Topotecan Vincristine	treatment	2	recruiting
NCT05272371	Immunotherapy With Dinutuximab Beta in Combination With Chemotherapy for the Treatment of Patients With Primary Neuroblastoma Refractory to Standard Therapy and With Relapsed or Progressive Disease	Dinutuximab	treatment	1	recruiting
NCT04221035	High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)	Busulfan Carboplatin Cisplatin Cyclophosphamide Dacarbazine Dinutuximab Doxorubicin Etoposide Ifosfamide Irinotecan Melphalan Temozolomide Thiotepa Vincristine Vindesine	treatment	3	recruiting
NCT04501757	Naxitamab and GM-CSF in People With Neuroblastoma	Naxitamab	Not Available	Not Available	no_longer_available
NCT06335745	PediCARE Health Equity Intervention in High-Risk Neuroblastoma	No drug interventions	supportive_care	Not Available	withdrawn
NCT06182410	Defibrotide Prophylaxis of Transplant Associated-Thrombotic Microangiopathy for Neuroblastoma	Defibrotide	supportive_care	2	withdrawn
NCT06607692	Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined with the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).	Lutetium Lu 177 dotatate Olaparib	treatment	2	recruiting
NCT05130255	GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2	No drug interventions	treatment	1	recruiting
NCT03061656	Tandem High Dose Chemotherapy With 131I-MIBG Treatment in High Risk Neuroblastoma	Carboplatin Cyclophosphamide Etoposide Melphalan Thiotepa	treatment	2	unknown_status
NCT03794349	Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma	Camptothecin Dinutuximab Eflornithine Irinotecan Sargramostim Temozolomide	treatment	2	active_not_recruiting
NCT03786783	Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma	Beta-D-Glucose Carboplatin Chloride ion Cisplatin Cyclophosphamide Daunorubicin Dexrazoxane Dinutuximab Doxorubicin Etoposide Isotretinoin Mechlorethamine Platinum Sargramostim Thiotepa Topotecan Tromethamine Vincristine	treatment	2	active_not_recruiting
NCT04751383	Testing the Combination of Two Immunotherapy Drugs (Magrolimab and Dinutuximab) in Patients With Relapsed or Refractory Neuroblastoma or Relapsed Osteosarcoma	Dinutuximab Magrolimab	treatment	1	active_not_recruiting
NCT01041638	Monoclonal Antibody Ch14.18, Sargramostim, Aldesleukin, and Isotretinoin After Autologous Stem Cell Transplant in Treating Patients With Neuroblastoma	Aldesleukin Dinutuximab Isotretinoin Sargramostim	treatment	3	completed